FDMT

4D Molecular Therapeutics, Inc.

27.23 USD
-0.03 (-0.11%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

4D Molecular Therapeutics, Inc. stock is up 53.06% since 30 days ago. The next earnings date is Mar 13, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 25% of the previous 3 February’s closed higher than January. In the last 10 Unusual Options Trades, there were 8 CALLs, 2 PUTs. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
07 Feb 16:11 16 Feb, 2024 30.00 CALL 386 1167
07 Feb 16:59 21 Jun, 2024 25.00 PUT 100 0
08 Feb 19:58 19 Jul, 2024 25.00 PUT 250 23
09 Feb 14:30 19 Jul, 2024 2.50 CALL 20 60
09 Feb 20:14 15 Mar, 2024 25.00 CALL 179 47
09 Feb 20:35 15 Mar, 2024 25.00 CALL 131 47
09 Feb 20:41 15 Mar, 2024 25.00 CALL 67 47
12 Feb 18:15 15 Mar, 2024 25.00 CALL 74 546
12 Feb 18:38 15 Mar, 2024 25.00 CALL 77 546
14 Feb 20:12 15 Mar, 2024 25.00 CALL 239 293

About 4D Molecular Therapeutics, Inc.

4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa, choroideremia, and 4 D-310.

  • Goldman Sachs
    Wed Feb 7, 07:16
    buy
    confirm
  • BMO Capital
    Mon Feb 5, 12:39
    buy
    confirm
  • RBC Capital
    Mon Feb 5, 09:54
    buy
    confirm
  • RBC Capital
    Mon Jan 29, 12:09
    buy
    confirm